Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.878%)
Open: 42.00
High: 42.00
Low: 42.00
Prev. Close: 42.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Synthomer predicts revenue decline amid challenges

Tue, 30th Jan 2024 12:27

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Berkeley Energia Ltd - Spain-focused clean energy company, focused on bringing the Salamanca project in Western Spain to production - Spot uranium prices jump 27% in the quarter to December 31, ending at USD91 per pound, and further rise to about USD100 per pound in January. "The outlook for nuclear power and the uranium market continued to strengthen during the quarter," Berkeley Energia says. Meanwhile, disagrees with decision by High Court of Justice of Castilla y Leon in Spain. The court upheld appeals to revoke judgements for authorisation of exceptional use of the land and the urbanism licence. Berkeley Energia plans to appeal the judgement at Spain's Supreme Court under Spanish law "to defend its position and take all necessary actions to preserve its rights."

----------

Cambridge Cognition Holdings PLC - Cambridgeshire, England-based company which develops and markets digital solutions to assess brain health - Swings to adjusted operating profit of GBP900,000 in 2023 from a loss of GBP2.1 million in 2022. Revenue grows 7.1% to GBP13.5 million in 2023 from GBP12.6 million. Looking ahead, company says: "There has been considerable merger & acquisition activity by large pharmaceutical companies in the central nervous system drug development sector recently and, together with an improving global economic outlook, that is expected to prompt further investment in CNS clinical trials." Chief Executive Officer Matthew Stork adds: "Despite challenging market conditions during 2023, the company has strengthened its technology platforms and commercial offering and is positioned to capitalise on the anticipated growth in the CNS drug development market. We continue to focus on delivering profitable growth and driving success over the medium-term." Cambridge Cognition will release its 2023 results in April.

----------

Diversified Energy Co PLC - owner of US oil and gas wells - Average net daily production edges up 1.3% to 136,800 barrels of oil equivalent in 2023, from 135,000 in 2022. Estimated adjusted earnings before interest, tax, depreciation and amortisation are set to rise at least 7.4% to between USD540 million and USD545 million in 2023, from USD503 million in 2022. CEO Rusty Hutson says: "Despite a challenging commodity price environment, we generated strong full year results, including growing Ebitda to a record level that exceeded consensus expectations," adding: "Diversified continues to grow as a solutions-based business, making it the right company at the right time."

----------

Flowtech Fluidpower PLC - Wilmslow, England-based supplier of technical fluid power products - Revenue in Great Britain declines 6.2% to GBP79.3 million in 2023, from GBP84.5 million in 2022. In Ireland, revenue climbs 13% to GBP22.0 million from GBP19.5 million. In the Benelux countries, revenue edges up 0.5% to GBP10.8 million. The company says that underlying profit for 2023 is anticipated to be in line with market expectations. Cites market expectations of underlying earnings before interest and tax of GBP6.0 million and underlying pretax profit of GBP4.6 million. Chair Roger McDowell says: "In 2023, we welcomed Mike England as our new CEO. With some significant team changes, he has focussed on implementing the near term performance improvement plan and the refreshed strategy to enable the firm platform from which the business can grow over the medium term. Whilst 2023 has been a more difficult year, I am confident that the actions Mike and his team are taking will drive strong returns in shareholder value."

----------

Harworth Group PLC - focused on the regeneration of land and property for sustainable development and investment - Expects EPRA net disposal value as at December 31 to be slightly ahead of current market consensus of 194.0 pence, which has a range of 189.5p to 195.6p. For December 31, 2022, the company had reported an EPRA NDV of 196.5p. The company says that its anticipated EPRA NDV "is the result of management actions undertaken on development sites to unlock high value uses, and positive progress with planning applications, which have underpinned valuation gains". Chief Executive Officer Lynda Shillaw says: "As we enter 2024, there are some signs of optimism in the macro environment whilst our key markets remain characterised by structural undersupply. We are encouraged that we are seeing continued good demand into the new year for our serviced residential land as well as occupier interest in our employment sites."

----------

Synthomer PLC - Essex, England-based chemicals manufacturer - Anticipates revenue decline of 16% to GBP2.0 billion in 2023 from GBP2.38 billion in 2022. Adjusted Ebitda will be between GBP140 million and GBP144 million in 2023. For 2022, Synthomer had reported Ebitda of GBP249.2 million. Year-end net debt is expected to decrease 51% to GBP499 million, ahead of its own expectations, from GBP1.02 billion a year prior. Synthomer cites "strong cash delivery in the final quarter" for the net debt reduction. The company says trading in the fourth quarter was consistent with trends throughout the year, with subdued volumes and limited visibility amid ongoing challenging macroeconomic conditions in the chemicals industry. Looking ahead, CEO Michael Willome says: "In the near term, our focus remains on enhancing our strong positions in key speciality end-markets, optimising our business portfolio and cost position, and sustaining our demonstrated ability to generate free cash flow despite the challenging demand environment."

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Oct 2014 09:08

Cambridge Cognition Launches New Product CTIS-Profile 2+

Read more
29 Sep 2014 11:54

DIRECTOR DEALINGS: Cambridge Cognition CEO And CFO Buy Shares

Read more
24 Sep 2014 08:58

DIRECTOR DEALINGS: Cambridge Cognition CEO And CFO Buy Shares

Read more
11 Sep 2014 10:21

Cambridge Cognition Narrows Pretax Loss In First-Half

Read more
13 Aug 2014 09:28

Cambridge Cognition Expands Partnership With Altreos Research

Read more
2 Jul 2014 08:50

Cambridge Cognition To Meet Full-Year Expectations As Half Year Ahead

Read more
26 Jun 2014 09:50

Cambridge Cognition Confident For Full-Year On Contract Wins

Read more
5 Jun 2014 09:34

Cambridge Cognition Holdings Signs Contracts For Cognitive Safety Trial

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Thursday that it has signed a contract for a global multi-year study in which its Cantab Solutions technology will be used to assess the cognitive safety of a new medicine under development for cardiovascular disease. The contra

Read more
3 Jun 2014 08:12

Cambridge Cognition Launches First iPad Product For Clinical Trials

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Tuesday that it had launched the first of its two iPad-based products on its Cantab Connect digital platform for use in clinical trials. Its product, called The Clinical Trials Information System Adverse Effects, allows for the

Read more
28 May 2014 10:08

Cambridge Cognition rolls out new health app in Lincolnshire

Computerised neuropsychological test specialists Cambridge Cognition announced its Cantab Mobile app has been released by North East Lincolnshire Clinical Commissioning Group into the medical sector. The group's app will be introduced to five GP surgeries, five pharmacies and Grimbsy hospital to he

Read more
28 May 2014 10:00

Cambridge Cognition Mobile App Rolled Out In North East Lincolnshire

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Wednesday that the North East Lincolnshire Clinical Commissioning Group has introduced its Cantab mobile app in five GP surgeries, five pharmacies and Grimsby hospital to help diagnose dementia earlier. The firm, which specialis

Read more
8 May 2014 11:58

Cambridge Cognition Reiterates Confidence On Return To Growth

LONDON (Alliance News) - Cambridge Cognition Holdings PLC Thursday reiterated confidence that it would be able to return to growth in 2014, in a statement ahead of its annual general meeting. The biotechnology company said that it had seen a positive start to trading in the first quarter of

Read more
2 Apr 2014 10:29

Cambridge Cognition Appoints Non-Executive Chairman

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Wednesday it has appointed Michael Lewis as non-executive Chairman. The company, which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, said Lewis will take over from

Read more
13 Mar 2014 12:08

Cambridge Cognition Confident For Return To Growth In 2014

LONDON (Alliance News) - Cambridge Cognition Holdings PLC expressed confidence Thursday that it would return to growth in 2014, after it posted a widened pretax loss in 2013 due to lower revenue. Cambridge Cognition provides computerised neuropsychological tests, particularly to enable earl

Read more
3 Mar 2014 11:00

Cambridge Cognition Launches Latest Research Software

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Monday it has launched the Cantab Research Suite, the latest offering in its cognitive testing platform for academic research. Cambridge, which specialises in computerised neuropsychological tests, such as those enabling the ear

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.